SLC5A2 and Hypoglycemia: The risk of hypoglycemia with SGLT-2 inhibitors is similar to that of placebo or other oral agents (metformin, DPP-4 inhibitors, thiazolidinediones, and α-Glucosidase inhibitors) when used as monotherapy (12–16).